Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter: .
“AI won’t replace pathologists.
But pathologists that use AI may replace those that don’t use it.”
Quoting Dana-Farber’s Breast Oncology Center’s post:
“Stuart Schnitt, MD discussed the role of Artificial Intelligence in Pathology in the special lecture on the future of pathology in Breast Cancer at the Harvard Breast Cancer Course.”
Source: Paolo Tarantino/X and Dana-Farber’s Breast Oncology Center/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field
